Laurus Labs Ltd. reported an 875% year-on-year increase in net profit to ₹195 crore for the quarter ended September, propelled by exceptional performance in its Contract Development and Manufacturing Organization (CDMO) segment and sustained momentum in the generics business.
The company’s revenues rose 35% to ₹1,653 crore, while EBITDA jumped 136% to ₹429 crore, expanding margins to 26% from 14.9% in the same quarter last year. Gross margins improved by 470 basis points to 59.9%, reflecting a more favorable product mix and operational efficiency gains.
“Our fundamentals remain strong,” said V. V. Ravi Kumar, CFO, Laurus Labs. “The CDMO and generics businesses continue to deliver, and operating leverage is playing out well.”
The CDMO segment posted a 53% rise in revenues to ₹518 crore, supported by late-phase and commercial deliveries in small molecules, while the generics segment grew 28% to ₹1,135 crore, driven by higher ARV volumes and increased supplies to developed markets.
Profit before tax surged to ₹270 crore, compared to ₹23 crore in the previous year, and diluted EPS climbed to ₹3.6, up from ₹0.4 in Q2FY25.
Laurus Labs said it continues to invest in capacity expansion and advanced technologies, including a $2 million strategic investment in Aarvik Therapeutics to gain access to next-generation Antibody-Drug Conjugate (ADC) platforms.
